Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about General Updates
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarey Drugs has submitted follow-up updates to its Extra-Ordinary General Meeting (EOGM) notice originally held on January 2, 2025, which pertains to a preferential issue of warrants. The company has added an Addendum to the Valuation Report dated April 17, 2025, as required by NSE, and made the Practicing Company Secretary Certificate (for warrants) and the original Valuation Report (dated December 27, 2024) available on its website. Importantly, the company clarified that there is no change in control resulting from this preferential issue. All 17 proposed allottees retain their current status post-issue — 11 promoter-group entities remain promoters, and 6 non-promoter allottees remain non-promoters. The allottee list includes promoter Bina, Mihir, Nimit Ghatalia and family, along with promoter entities like Enam Organics, Nimit Impex, Suraj Tradelinks, and Worth Investment, plus non-promoters like Archana Wani, Priti Shah, and Vaishali Aggarwal.
This is largely a procedural clarification with no change in ownership structure or control — existing promoters and non-promoters keep their pre and post-issue status, which should reassure shareholders concerned about dilution or ownership shifts. The addition of the valuation addendum and secretary certificate simply strengthens compliance disclosures for the warrant preferential issue, with limited direct impact on stock price.